D
Donna Holloway
Researcher at Amgen
Publications - 9
Citations - 3766
Donna Holloway is an academic researcher from Amgen. The author has contributed to research in topics: Bone resorption & Bone remodeling. The author has an hindex of 9, co-authored 9 publications receiving 3643 citations.
Papers
More filters
Journal ArticleDOI
Denosumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung,E. Michael Lewiecki,Stanley B. Cohen,Michael A. Bolognese,Grattan Woodson,Alfred H. Moffett,Munro Peacock,Paul D. Miller,Samuel N. Lederman,Charles H. Chesnut,Douglas Lain,Alan Kivitz,Donna Holloway,Charlie Zhang,Mark C. Peterson,Pirow J. Bekker +15 more
TL;DR: The efficacy and safety of subcutaneously administered denosumab were evaluated in postmenopausal women with low bone mineral density and changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline p...
Journal ArticleDOI
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women
Pirow Bekker,Donna Holloway,Amy S Rasmussen,Robyn Murphy,Steven W. Martin,Philip T. Leese,Gregory B Holmes,Colin R. Dunstan,Alex M. DePaoli +8 more
TL;DR: The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women.
Journal ArticleDOI
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Jean-Jacques Body,Thierry Facon,Robert E. Coleman,Allan Lipton,Filip Geurs,Michelle Fan,Donna Holloway,Mark C. Peterson,Pirow Bekker +8 more
TL;DR: A single s.c. dose of denosumab given to patients with multiple myeloma or bone metastases from breast cancer was well tolerated and reduced bone resorption for at least 84 days, and the effect diminished progressively through follow-up.
Journal ArticleDOI
The effect of a single dose of osteoprotegerin in postmenopausal women.
Pirow Bekker,Donna Holloway,Arline Nakanishi,Michael Arrighi,Philip T. Leese,Colin R. Dunstan +5 more
TL;DR: This study indicates that a single sc injection of OPG is effective in rapidly and profoundly reducing bone turnover for a sustained period and that OPG therefore may be effective in treatment of bone diseases characterized by increased bone resorption such as osteoporosis.
Journal ArticleDOI
A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
Jean-Jacques Body,Philip Greipp,Robert E. Coleman,Thierry Facon,Filip Geurs,Jean-Paul Fermand,Jean-Luc Harousseau,Allan Lipton,Xavier Mariette,Catherine D. Williams,Arline Nakanishi,Donna Holloway,Steven W. Martin,Colin R. Dunstan,Pirow Bekker +14 more
TL;DR: AMGN‐0007 is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease and a decoy receptor for OPG ligand (OPGL)